The effectiveness and sustainability of health outcomes from a holistic digital weight‐loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK

Abstract

AbstractAimTo measure the effectiveness and sustainability of the Juniper UK digital weight‐loss service (DWLS), which delivers 6 months of personalized, proactive lifestyle coaching supplemented with tirzepatide to patients through a multidisciplinary team (MDT).MethodsAn observer‐blinded randomized controlled trial (RCT) will be conducted on a cohort of non‐diabetic patients of the Juniper DWLS in the UK. Participants in both the intervention and control groups will receive weekly subcutaneous injections of 2.5 mg tirzepatide for 4 weeks, uptitrating the dose to 5.0 mg from weeks 5 to 8, and by 2.5 mg every 4 weeks until reaching 15 mg in week 21, which they will maintain until the end of the intervention period at 6 months, when participants will be taken off the medication. The intervention group will receive personalized weeklylifestyle coaching with a focus on protein intake and resistance training for 6 months. Participants in the control group will attend a diet and exercise group counselling session at programme inception and will be sent a summary of the session's content at months 2 and 4. Aside from these events, health coaches will only interact with control group participants on a reactive basis. From month 6 to month 12, participants from both groups will no longer have access to their MDTs. The trial's co‐primary endpoints include weight loss, fat‐free to fat‐mass ratio and composite strength measures at 12 months (6 months following the end of treatment), compared with baseline. Secondary endpoints include percentage change in weight, fat‐free to fat‐mass ratio, and composite strength from baseline to 6 months, side effect incidence, and change in cardiometabolic risk factors at 12 months. Quality of life and programme engagement represent the study's exploratory endpoints.ResultsA total of 688 participants enrolled in the study, with a mean age of 44.6 (± 11.4) years and a mean body mass index of 34.8 (± 7.5) kg/m2; 81.0% of participants are women, and 72.8% are of White ethnicity. More than three‐quarters of participants have at least one co‐morbidity, with dyslipidaemia (42.4%), hypertension (35.3%) and high cholesterol (31.8%) being the most prevalent conditions.ConclusionsThis RCT will be the first to assess the effectiveness and sustainability of a real‐world intensive, multidisciplinary DWLS, and it should highlight the potential of such a service for long‐term obesity treatment compared with programmes that deliver standard health counselling.